Literature DB >> 31229951

Early intensive treatment normalises excess mortality in ACPA-negative RA but not in ACPA-positive RA.

Xanthe Me Matthijssen1, Tom Wj Huizinga2, Ellis Niemantsverdriet2, Annette Hm van der Helm-van Mil2,3.   

Abstract

Entities:  

Keywords:  early rheumatoid arthritis; epidemiology; rheumatoid arthritis

Mesh：

Substances：

Year:  2019        PMID： 31229951      PMCID： PMC7116088          DOI： 10.1136/annrheumdis-2019-215843

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN： 0003-4967            Impact factor:   19.103


× No keyword cloud information.
  8 in total

1.  No increased mortality in incident cases of rheumatoid arthritis during the new millennium.

Authors:  K Puolakka; H Kautiainen; T Pohjolainen; L Virta
Journal:  Ann Rheum Dis       Date:  2010-05-06       Impact factor: 19.103

2.  Normal mortality of the COBRA early rheumatoid arthritis trial cohort after 23 years of follow-up.

Authors:  Pomme B M Poppelaars; Lilian H D van Tuyl; Maarten Boers
Journal:  Ann Rheum Dis       Date:  2019-02-26       Impact factor: 19.103

3.  Long-Term Outcomes of Patients With Recent-Onset Rheumatoid Arthritis After 10 Years of Tight Controlled Treatment: A Randomized Trial.

Authors:  Iris M Markusse; Gülsah Akdemir; Linda Dirven; Yvonne P M Goekoop-Ruiterman; Johannes H L M van Groenendael; K Huub Han; T H Esmeralda Molenaar; Saskia Le Cessie; Willem F Lems; Peter A H M van der Lubbe; Pit J S M Kerstens; André J Peeters; H Karel Ronday; Peter B J de Sonnaville; Irene Speyer; Theo Stijnen; Saskia Ten Wolde; Tom W J Huizinga; Cornelia F Allaart
Journal:  Ann Intern Med       Date:  2016-03-01       Impact factor: 25.391

4.  Mortality in rheumatoid arthritis patients with disease onset in the 1980s.

Authors:  E Lindqvist; K Eberhardt
Journal:  Ann Rheum Dis       Date:  1999-01       Impact factor: 19.103

5.  Improved treatment strategies reduce the increased mortality risk in early RA patients.

Authors:  Jessica A B van Nies; Zuzana de Jong; Annette H M van der Helm-van Mil; Rachel Knevel; Saskia Le Cessie; Tom W J Huizinga
Journal:  Rheumatology (Oxford)       Date:  2010-08-09       Impact factor: 7.580

6.  Mortality following new-onset Rheumatoid Arthritis: has modern Rheumatology had an impact?

Authors:  Marie Holmqvist; Lotta Ljung; Johan Askling
Journal:  Ann Rheum Dis       Date:  2017-09-26       Impact factor: 19.103

7.  Rheumatoid arthritis and excess mortality: down but not out. A primary care cohort study using data from Clinical Practice Research Datalink.

Authors:  Abhishek Abhishek; Georgina Nakafero; Chang-Fu Kuo; Christian Mallen; Weiya Zhang; Matthew J Grainge; Michael Doherty
Journal:  Rheumatology (Oxford)       Date:  2018-06-01       Impact factor: 7.580

8.  Twenty-Year Outcome and Association Between Early Treatment and Mortality and Disability in an Inception Cohort of Patients With Rheumatoid Arthritis: Results From the Norfolk Arthritis Register.

Authors:  James M Gwinnutt; Deborah P M Symmons; Alexander J MacGregor; Jacqueline R Chipping; Tarnya Marshall; Mark Lunt; Suzanne M M Verstappen
Journal:  Arthritis Rheumatol       Date:  2017-07-10       Impact factor: 10.995
  8 in total
  2 in total

1.  Influence of initial glucocorticoid co-medication on mortality and hospitalization in early inflammatory arthritis: an investigation by record linkage of clinical and administrative databases.

Authors:  Garifallia Sakellariou; Carlo Alberto Scirè; Federica Rumi; Greta Carrara; Anna Zanetti; Carlo Cerra; Simona Migliazza; Serena Bugatti; Carlomaurizio Montecucco
Journal:  Arthritis Res Ther       Date:  2022-06-16       Impact factor: 5.606

2.  Efficacy and safety of sarilumab in combination with csDMARDs or as monotherapy in subpopulations of patients with moderately to severely active rheumatoid arthritis in three phase III randomized, controlled studies.

Authors:  Mark C Genovese; Roy Fleischmann; Alan Kivitz; Eun-Bong Lee; Hubert van Hoogstraten; Toshio Kimura; Gregory St John; Erin K Mangan; Gerd R Burmester
Journal:  Arthritis Res Ther       Date:  2020-06-10       Impact factor: 5.156
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.